Gold Prices: De-Dollarization, Inflation, and $3,000 Gold—What You Need to Know Now

Gold has been in the headlines over the last few months, perhaps more so now than in years. This heightened attention stems from shifts in global conditions, including worldwide inflation, escalating geopolitical tensions, a surge in central bank gold purchases, de-dollarization efforts, and the influence of BRICS nations. If you follow financial media, $3,000 an…

Read More

The Bullish Case for Small Caps vs. Large Caps

Will small cap stocks finally take on a leadership role in 2025? In this video, Dave provides a thorough technical analysis discussion of the Russell 2000 ETF (IWM) and how that compares to the current technical configuration of the S&P 500 index. He also shares three charts he’ll be watching in the coming weeks to…

Read More

Freegold Ventures

Overview ‘Explore the unparalleled potential of Freegold Ventures (TSX:FVL,OTCQX:FGOVF), an exceptional exploration company with its flagship asset situated in the renowned Tintina gold belt. Golden Summit, located just a 30-minute drive from Fairbanks, now hosts what is believed to be one of the largest undeveloped gold resources in North America.’ Freegold’s Shorty Creek project, meanwhile,…

Read More

Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition

Pharmaceutical giant Johnson & Johnson (J&J) (NYSE:JNJ) has announced plans to acquire Intra-Cellular Therapies (NASDAQ:ITCI) in a US$14.6 billion deal, marking the largest acquisition for the sector in over two years. The purchase, which is expected to close later this year pending regulatory and shareholder approvals, will give J&J access to Intra-Cellular’s portfolio of treatments…

Read More

Top 4 Canadian Biotech Stocks (Updated January 2025)

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare. In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies. According to Grandview Research, the global biotech market is expected to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value…

Read More
Back To Top